ASCO GI 2024 | Exploring novel SCCA treatments: CD4 vaccine + checkpoint inhibitor

Stefano Kim, MD, Centre Hospitalier Universitaire de Besançon, Besançon, France, discusses the exploration of novel treatments for squamous cell anal carcinoma (SCCA). His team is evaluating a universal tumor vaccine, specifically a CD4 human telomerase vaccine, in combination with a checkpoint inhibitor. The results so far are encouraging, and they are considering the future use of this treatment, possibly as a first-line maintenance treatment for patients without a complete response. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.